新闻特写：为抗击疫情，临床医生寄希望于 repurposed drugs。注：“repurposed drugs”直译为“重新利用的药物”，在医学领域可能有特定含义，比如“旧药新用”等，需结合上下文准确理解其确切意思。 - Suppr

Suppr

超能文献

News Feature: To counter the pandemic, clinicians bank on repurposed drugs.

作者信息

Madhusoodanan Jyoti

出版信息

Proc Natl Acad Sci U S A. 2020 May 19;117(20):10616-10620. doi: 10.1073/pnas.2007346117. Epub 2020 Apr 29.

DOI:10.1073/pnas.2007346117

PMID:32350142

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7245123/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/270f/7245123/fe8baccbaf42/pnas.2007346117fig01.jpg

相似文献

News Feature: To counter the pandemic, clinicians bank on repurposed drugs.

Proc Natl Acad Sci U S A. 2020 May 19;117(20):10616-10620. doi: 10.1073/pnas.2007346117. Epub 2020 Apr 29.

Audio Interview: Approaches to Covid-19 Vaccines and Antivirals.

N Engl J Med. 2020 Apr 23;382(16):e58. doi: 10.1056/NEJMe2012889.

The Landscape of Prescription Drug Shortages During the COVID-19 Pandemic.

J Med Toxicol. 2020 Jul;16(3):311-313. doi: 10.1007/s13181-020-00786-4. Epub 2020 May 27.

COVID-19: A Defining Moment for Clinical Pharmacology?

Clin Pharmacol Ther. 2020 Jul;108(1):11-15. doi: 10.1002/cpt.1876.

How to Discover Antiviral Drugs Quickly.

N Engl J Med. 2020 Jun 4;382(23):2261-2264. doi: 10.1056/NEJMcibr2007042. Epub 2020 May 20.

Clinical Trials of Repurposed Antivirals for SARS-CoV-2.

Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01101-20.

Science in the Wake of the Pandemic: How Will COVID-19 Change the Way We Do Research?

Mol Cell. 2020 Jul 2;79(1):9-10. doi: 10.1016/j.molcel.2020.06.024.

Structural Biology Aids the Research of New Anti-COVID-19 Drugs.

Curr Org Synth. 2020;17(3):162-163. doi: 10.2174/157017941703200610221527.

COVID-19: Stay Cool toward Corticosteroids.

Keio J Med. 2020 Jun 25;69(2):27-29. doi: 10.2302/kjm.2020-0007-LE. Epub 2020 May 30.

Repurposing old drugs as antiviral agents for coronaviruses.

Biomed J. 2020 Aug;43(4):368-374. doi: 10.1016/j.bj.2020.05.003. Epub 2020 May 23.

引用本文的文献

A Workflow of Integrated Resources to Catalyze Network Pharmacology Driven COVID-19 Research.

J Chem Inf Model. 2022 Feb 14;62(3):718-729. doi: 10.1021/acs.jcim.1c00431. Epub 2022 Jan 20.

Multi-conformation representation of Mpro identifies promising candidates for drug repurposing against COVID-19.

J Mol Model. 2021 Apr 17;27(5):128. doi: 10.1007/s00894-021-04732-1.

A Workflow of Integrated Resources to Catalyze Network Pharmacology Driven COVID-19 Research.

bioRxiv. 2020 Nov 5:2020.11.04.369041. doi: 10.1101/2020.11.04.369041.

GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response.

Front Immunol. 2020 Jun 26;11:1638. doi: 10.3389/fimmu.2020.01638. eCollection 2020.

本文引用的文献

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.

Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.

J Biol Chem. 2020 May 15;295(20):6785-6797. doi: 10.1074/jbc.RA120.013679. Epub 2020 Apr 13.

Compassionate Use of Remdesivir for Patients with Severe Covid-19.

N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10.

Effectiveness of convalescent plasma therapy in severe COVID-19 patients.

Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6.

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.

Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.

J Biol Chem. 2020 Apr 10;295(15):4773-4779. doi: 10.1074/jbc.AC120.013056. Epub 2020 Feb 24.

First Case of 2019 Novel Coronavirus in the United States.

N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.

Virol J. 2005 Aug 22;2:69. doi: 10.1186/1743-422X-2-69.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

News Feature: To counter the pandemic, clinicians bank on repurposed drugs.

Proc Natl Acad Sci U S A. 2020 May 19;117(20):10616-10620. doi: 10.1073/pnas.2007346117. Epub 2020 Apr 29.

Audio Interview: Approaches to Covid-19 Vaccines and Antivirals.

N Engl J Med. 2020 Apr 23;382(16):e58. doi: 10.1056/NEJMe2012889.

The Landscape of Prescription Drug Shortages During the COVID-19 Pandemic.

J Med Toxicol. 2020 Jul;16(3):311-313. doi: 10.1007/s13181-020-00786-4. Epub 2020 May 27.

COVID-19: A Defining Moment for Clinical Pharmacology?

Clin Pharmacol Ther. 2020 Jul;108(1):11-15. doi: 10.1002/cpt.1876.

How to Discover Antiviral Drugs Quickly.

N Engl J Med. 2020 Jun 4;382(23):2261-2264. doi: 10.1056/NEJMcibr2007042. Epub 2020 May 20.

Clinical Trials of Repurposed Antivirals for SARS-CoV-2.

Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01101-20.

Science in the Wake of the Pandemic: How Will COVID-19 Change the Way We Do Research?

Mol Cell. 2020 Jul 2;79(1):9-10. doi: 10.1016/j.molcel.2020.06.024.

Structural Biology Aids the Research of New Anti-COVID-19 Drugs.

Curr Org Synth. 2020;17(3):162-163. doi: 10.2174/157017941703200610221527.

COVID-19: Stay Cool toward Corticosteroids.

Keio J Med. 2020 Jun 25;69(2):27-29. doi: 10.2302/kjm.2020-0007-LE. Epub 2020 May 30.

Repurposing old drugs as antiviral agents for coronaviruses.

Biomed J. 2020 Aug;43(4):368-374. doi: 10.1016/j.bj.2020.05.003. Epub 2020 May 23.

引用本文的文献

A Workflow of Integrated Resources to Catalyze Network Pharmacology Driven COVID-19 Research.

J Chem Inf Model. 2022 Feb 14;62(3):718-729. doi: 10.1021/acs.jcim.1c00431. Epub 2022 Jan 20.

Multi-conformation representation of Mpro identifies promising candidates for drug repurposing against COVID-19.

J Mol Model. 2021 Apr 17;27(5):128. doi: 10.1007/s00894-021-04732-1.

A Workflow of Integrated Resources to Catalyze Network Pharmacology Driven COVID-19 Research.

bioRxiv. 2020 Nov 5:2020.11.04.369041. doi: 10.1101/2020.11.04.369041.

GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response.

Front Immunol. 2020 Jun 26;11:1638. doi: 10.3389/fimmu.2020.01638. eCollection 2020.

本文引用的文献

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.

Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.

J Biol Chem. 2020 May 15;295(20):6785-6797. doi: 10.1074/jbc.RA120.013679. Epub 2020 Apr 13.

Compassionate Use of Remdesivir for Patients with Severe Covid-19.

N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10.

Effectiveness of convalescent plasma therapy in severe COVID-19 patients.

Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6.

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.

Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.

J Biol Chem. 2020 Apr 10;295(15):4773-4779. doi: 10.1074/jbc.AC120.013056. Epub 2020 Feb 24.

First Case of 2019 Novel Coronavirus in the United States.

N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.

Virol J. 2005 Aug 22;2:69. doi: 10.1186/1743-422X-2-69.